AUTL

Autolus Therapeutics plc - ADR

1.92

USD

-0.03

-1.64%

Sep 24, 11:48 UTC -4

Open

Autolus Therapeutics plc - ADR Profile

About

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom.

Info & Links

CEO

Christian Itin

Headquarters

THE MEDIAWORKS,191 WOOD LANE
LONDON, X0 W12 7FP, UNITED KINGDOM

Auditor

Ernst & Young LLP

Share holders

Employees

752

Autolus Therapeutics plc - ADR Statistics

Valuation Measures

Market Capitalization²

510.50M

Enterprise Value

415.31M

Enterprise Value/EBITDA(ttm)

-1.75

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

4.60

Price to Book(mrq)

7.22

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

5.52%

Operating Margin(ttm)

-238.66%

Profit Margin(ttm)

-275.97%

Return on Equity(ttm)

-178.66%

Return on Invested Capital(ttm)

-158.11%

Return on Assets(ttm)

-49.34%

Income Statement

Revenue(ttm)

117.39M

Revenue Per Share(ttm)

0.44

Gross Profit(ttm)

18.38M

EBITDA(ttm)³

-236.92M

Net Income Available to Common(ttm)

-280.16M

Diluted EPS(ttm)

-1.06

Share Statistics

Beta (5Y Monthly)

2.10

52-Week Change

42.07%

S&P 500 52-Week Change

19.49%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

266.16M

Dividend Yield

0.00%

Float⁴

197.76M

% Held by Insiders

25.70%

% Held by Institutions

72.83%

Balance Sheet

Total Cash(mrq)

203.13M

Total Cash Per Share(mrq)

0.76

Total Debt(mrq)

77.72M

Total Debt/Equity(mrq)

103.85%

Current Ratio(mrq)

4.89%

Quick Ratio(mrq)

4.40%

Book Value Per Share(mrq)

0.28

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.34

Free Cash Flow(ytd)

-93.99M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.